Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies

Barnes, Christopher O., West, Anthony P., Huey-Tubman, Kathryn E., Hoffmann, Magnus A.G., Sharaf, Naima G., Hoffman, Pauline R., Koranda, Nicholas, Gristick, Harry B. +15 more·2020·Cell
DOI 10.1016/j.cell.2020.06.025

Cited by (803)

Items 101–200 of 803

  1. Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2
    Xiaoyu Sun, Chunyan Yi, Yuanfei Zhu, Longfei Ding, Shuai Xia, Xingchen Chen, Mu Liu, Chenjian Gu, Xiaoxia Lü, Yadong Fu et al. · 2022 · Nature Microbiology
  2. Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice
    P. Pymm, Amy Adair, L. Chan, James P. Cooney, F. Mordant, C. Allison, E. Lopez, E. Haycroft, O, M. Neill et al. · 2021 · Proceedings of the National Academy of Sciences of the United States of America
  3. A compendium answering 150 questions on COVID‐19 and SARS‐CoV‐2
    Carmen Riggioni, Pasquale Comberiati, Mattia Giovannini, Ioana Octavia Agache, Mübeccel Akdiş, Magna Alves‐Correia, Josep M. Antó, Alessandra Arcolacı, Ahmet Kürşat Azkur, Dilek Azkur et al. · 2020 · Allergy
  4. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
    McCallum, Matthew, Marco, Anna De, Lempp, Florian, Tortorici, M. Alejandra, Pinto, Dora, Walls, Alexandra C., Beltramello, Martina, Chen, Alex, Liu, Zhuoming, Zatta, Fabrizia et al. · 2021
  5. Antibody Persistence in the Six Months Following SARS-CoV-2 Infection Among Hospital Workers
    Arnaud Grégoire L’Huillier, Benjamin Meyer, Diego O. Andrey, Isabelle Arm‐Vernez, Stéphanie Baggio, Arnaud M. Didierlaurent, Christiane Sigrid Eberhardt, Isabella Eckerle, Carole Grasset Salomon, Angela Huttner et al. · 2020 · Clinical Microbiology and Infection
  6. Neutralizing antibodies for the prevention and treatment of COVID-19
    Lanying Du, Yang Yang, Xiujuan Zhang · 2021 · Cellular and Molecular Immunology
  7. Antibody and B cell responses to SARS-CoV-2 infection and vaccination
    Katharina Röltgen, Scott Dexter Boyd · 2021 · Cell Host & Microbe
  8. mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants
    Aurélien Sokal, Giovanna Barba Spaeth, Ignacio Fernández, Matteo Broketa, Imane Azzaoui, Andréa de La Selle, Alexis Vandenberghe, Slim Fourati, Anaïs Roeser, Annalisa Meola et al. · 2021 · Immunity
  9. Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern
    Wenwei Li, Yaozong Chen, Jérémie Prévost, Irfan Ullah, Maolin Lu, Shang Yu Gong, Alexandra Tauzin, Romain Gasser, Dani Vézina, Sai Priya Anand et al. · 2021 · Cell Reports
  10. Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT)
    Benjamin Meyer, Johan H J Reimerink, Giulia Torriani, Fion Brouwer, Gert-Jan Godeke, Sabine Yerly, Marieke N. Hoogerwerf, Nicolas Vuilleumier, Laurent Kaiser, Isabella Eckerle et al. · 2020 · Emerging Microbes & Infections
  11. COVID-19 and cancer: From basic mechanisms to vaccine development using nanotechnology
    Hyun Jee Han, Chinekwu Sherridan Nwagwu, Obumneme Benneth Anyim, Chinedu Ekweremadu, San Kim · 2020 · International Immunopharmacology
  12. Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19
    Canrong Wu, Wanchao Yin, Yi Jiang, H. Eric Xu · 2022 · Acta Pharmacologica Sinica
  13. Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2
    Qi Zhang, Bin Ju, Jiwan Ge, Jasper Fuk‐Woo Chan, Lin Cheng, Ruoke Wang, Weijin Huang, Mengqi Fang, Peng Chen, Bing Zhou et al. · 2021 · Nature Communications
  14. Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants
    Anshumali Mittal, Arun Khattri, Vikash Verma · 2022 · PLoS Pathogens
  15. COVID-19: Mechanisms of Vaccination and Immunity
    Daniel E. Speiser, Martin F. Bachmann · 2020 · Vaccines
  16. Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike
    Pei Tong, Avneesh Kumar Gautam, Ian W. Windsor, Meghan E. Travers, Yuezhou Chen, Nicholas Garcia, Noah B. Whiteman, Lindsay G. A. McKay, Nadia Storm, Lauren E. Malsick et al. · 2021 · Cell
  17. Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates
    Linling He, Xiaohe Lin, Ying Wang, Ciril Abraham, Cindy Sou, Timothy Ngo, Yi Zhang, Ian A. Wilson, Jiang Zhu · 2021 · Science Advances
  18. Fruitful Neutralizing Antibody Pipeline Brings Hope To Defeat SARS-Cov-2
    Alex Renn, Ying Fu, Xin Hu, Matthew D. Hall, Anton M. Simeonov · 2020 · Trends in Pharmacological Sciences
  19. Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies
    Claudia A. Jette, Alexander A. Cohen, Priyanthi N.P. Gnanapragasam, Frauke Muecksch, Yu Erica Lee, Kathryn E. Huey‐Tubman, Fabian Schmidt, Théodora Hatziioannou, Paul D. Bieniasz, Michel C. Nussenzweig et al. · 2021 · Cell Reports
  20. High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models
    Wei Li, Alexandra Schäfer, Swarali S. Kulkarni, Xianglei Liu, David R. Martinez, Chuan Chen, Zehua Sun, Sarah R. Leist, Aleksandra K. Drelich, Liyong Zhang et al. · 2020 · Cell
  21. Structural basis for the different states of the spike protein of SARS-CoV-2 in complex with ACE2
    Renhong Yan, Yuanyuan Zhang, Yaning Li, Fangfei Ye, Yingying Guo, Lu Xia, Xinyue Zhong, Ximin Chi, Qiang Zhou · 2021 · Cell Research
  22. Deep mutational learning predicts ACE2 binding and antibody escape to combinatorial mutations in the SARS-CoV-2 receptor-binding domain
    Joseph M. Taft, Cédric R. Weber, Beichen Gao, Roy A. Ehling, Jiami Han, Lester Frei, Sean W. Metcalfe, Max D. Overath, Alexander Yermanos, William Kelton et al. · 2022 · Cell
  23. Immunological memory diversity in the human upper airway
    Sydney I. Ramirez, Farhoud Faraji, L. Benjamin Hills, Paul G. Lopez, Benjamin Goodwin, Hannah D. Stacey, Henry J. Sutton, Kathryn M. Hastie, Erica Ollmann Saphire, Hyun Jik Kim et al. · 2024 · Nature
  24. A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection
    Tingting Li, Hongmin Cai, Hebang Yao, Bingjie Zhou, Ning Zhang, Martje Fentener van Vlissingen, Thijs Kuiken, Wenyu Han, Corine H. GeurtsvanKessel, Yuhuan Gong et al. · 2021 · Nature Communications
  25. Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects
    Madeleine F. Jennewein, Anna J. MacCamy, Nicholas R. Akins, Junli Feng, Leah J. Homad, Nicholas K. Hurlburt, Emilie Seydoux, Yu-Hsin Wan, Andrew B. Stuart, Venkata Viswanadh Edara et al. · 2021 · Cell Reports
  26. Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes
    Dapeng Sun, Zhe Sang, Yong Joon Kim, Yufei Xiang, Tomer Cohen, Anna K. Belford, Alexis Huet, James F. Conway, Ji Sun, Derek J. Taylor et al. · 2021 · Nature Communications
  27. Cross-reactive antibodies after SARS-CoV-2 infection and vaccination
    Marloes Grobben, Karlijn van der Straten, Philip J. M. Brouwer, Mitch Brinkkemper, Pauline Maisonnasse, Nathalie Dereuddre‐Bosquet, Brent Appelman, A. H. Ayesha Lavell, Lonneke A. van Vught, Judith A. Burger et al. · 2021 · eLife
  28. Cryo-EM structures of SARS-CoV-2 Omicron BA.2 spike
    Victoria Stalls, Jared J. Lindenberger, S. Gobeil, Rory C. Henderson, Robert Parks, Maggie Barr, Margaret Deyton, Mitchell Martin, Katarzyna Janowska, Xiao Huang et al. · 2022 · Cell Reports
  29. Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies
    Dufloo, Jérémy, Grzelak, Ludivine, Staropoli, Isabelle, Madec, Yoann, Tondeur, Laura, Anna, François, Pelleau, Stéphane, Wiedemann, Aurélie, Planchais, Cyril, Buchrieser, Julian et al. · 2021 · Cell Reports Medicine
  30. Architecture and antigenicity of the Nipah virus attachment glycoprotein
    Zhaoqian Wang, Moushimi Amaya, Amin Addetia, Ha V. Dang, Gabriella Reggiano, Lianying Yan, Andrew C. Hickey, Frank DiMaio, Christopher C. Broder, David Veesler · 2022 · Science
  31. A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes
    Yu Guo, Lisu Huang, Guangshun Zhang, Yanfeng Yao, He Zhou, Shū Shěn, Bingqing Shen, Bo Li, Xin Li, Qian Zhang et al. · 2021 · Nature Communications
  32. Structural analysis of receptor binding domain mutations in SARS-CoV-2 variants of concern that modulate ACE2 and antibody binding
    Dhiraj Mannar, James W. Saville, Xing Quan Zhu, Shanti Swaroop Srivastava, Alison Berezuk, Steven Zhou, Katharine S. Tuttle, Andrew Kim, Wei Li, Dimiter Stanchev Dimitrov et al. · 2021 · Cell Reports
  33. The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies
    Anastassios C. Papageorgiou, Imran Mohsin · 2020 · Cells
  34. B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV
    Johannes F. Scheid, Christopher O. Barnes, Basak Eraslan, Andrew Hudak, Jennifer R. Keeffe, Lisa A. Cosimi, Eric Brown, Frauke Muecksch, Yiska Weisblum, Shuting Zhang et al. · 2021 · Cell
  35. Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection
    H. Yao, Yao Sun, Yong-Qiang Deng, Nan Wang, Yongcong Tan, Na-Na Zhang, Xiao-Feng Li, Chao Kong, Yan-Peng Xu, Qi Chen et al. · 2020 · Cell Research
  36. Computational Insights into the Conformational Accessibility and Binding Strength of SARS-CoV-2 Spike Protein to Human Angiotensin-Converting Enzyme 2
    Cheng Peng, Zhengdan Zhu, Yulong Shi, Xiaoyu Wang, Kaijie Mu, Yanqing Yang, Xinben Zhang, Zhijian Xu, Weiliang Zhu · 2020 · The Journal of Physical Chemistry Letters
  37. Germline-encoded amino acid-binding motifs drive immunodominant public antibody responses
    Ellen L. Shrock, R. Timms, T. Kula, E. L. Mena, A. West, Rui Guo, I-Hsiu Lee, Alexander A. Cohen, Lindsay G. A. McKay, Cai-Hong Bi et al. · 2023 · Science
  38. Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants
    Tingting Li, Wenhui Xue, Qingbing Zheng, Shuo Song, Chuanlai Yang, Hualong Xiong, Sibo Zhang, Minqing Hong, Yali Zhang, Hai Jing Yu et al. · 2021 · Nature Communications
  39. Structural Basis of SARS-CoV-2 and SARS-CoV Antibody Interactions
    Edem Gavor, Yeu Khai Choong, Shi Yin Er, Hariharan Sivaraman, Jayaraman Sivaraman · 2020 · Trends in Immunology
  40. Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection
    Wei Li, Chuan Chen, Aleksandra K. Drelich, David R. Martinez, Lisa E. Gralinski, Zehua Sun, Alexandra Schäfer, Swarali S. Kulkarni, Xianglei Liu, Sarah R. Leist et al. · 2020 · Proceedings of the National Academy of Sciences
  41. Inhalable nanovaccine with biomimetic coronavirus structure to trigger mucosal immunity of respiratory tract against COVID-19
    Bin Zheng, Wenchang Peng, Mingming Guo, Mengqian Huang, Yuxuan Gu, Tao Wang, Guangjian Ni, Dong Ming · 2021 · Chemical Engineering Journal
  42. A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma
    Craig W. Fenwick, Priscilla Turelli, Céline Pellaton, Alex Farina, Jérémy Campos, Charlène Raclot, Florence Pojer, Valeria Cagno, Semira Gonseth, Valérie D’Acremont et al. · 2021 · Science Translational Medicine
  43. The immunodominant and neutralization linear epitopes for SARS-CoV-2
    Shuai Lu, Xi-xiu Xie, Lei Zhao, Bin Wang, Jie Zhu, Ting-rui Yang, Guang-wen Yang, Mei Ji, Cui-ping Lv, Jian Xue et al. · 2021 · Cell Reports
  44. Sequence signatures of two public antibody clonotypes that bind SARS-CoV-2 receptor binding domain
    Tan, Timothy J. C., Yuan, Meng, Kuzelka, Kaylee, Padron, Gilberto C., Beal, Jacob R., Chen, Xin, Wang, Yiquan, Rivera-Cardona, Joel, Zhu, Xueyong, Stadtmueller, Beth M. et al. · 2021 · Nature Communications
  45. Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants
    Lok Bahadur Shrestha, Nicodemus T. Tedla, Rowena Anne Bull · 2021 · Frontiers in Immunology
  46. SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies
    S. Momsen Reincke, Meng Yuan, Hans‐Christian Kornau, Victor M. Corman, Scott van Hoof, Elisa Sánchez-Sendín, Melanie Ramberger, Wenli Yu, Yuanzi Hua, Henry J. Tien et al. · 2022 · Science
  47. Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers
    Edurne Rujas, Iga Kucharska, Yong Zi Tan, Samir Benlekbir, Hong Cui, Tiantian Zhao, Gregory A. Wasney, Patrick Budylowski, Furkan Guvenc, Jocelyn C. Newton et al. · 2021 · Nature Communications
  48. Therapeutic Strategies Against COVID-19 and Structural Characterization of SARS-CoV-2: A Review
    Gi Uk Jeong, Hanra Song, Gun Young Yoon, Doyoun Kim, Young‐Chan Kwon · 2020 · Frontiers in Microbiology
  49. The potential significance of high avidity immunoglobulin G (IgG) for protective immunity towards SARS-CoV-2
    Georg Bauer · 2021 · International Journal of Infectious Diseases
  50. Discovery of Cyclic Peptide Ligands to the SARS-CoV-2 Spike Protein Using mRNA Display
    Alexander R. Norman, Charlotte Franck, Mary Christie, Paige M. E. Hawkins, Karishma Patel, Anneliese S. Ashhurst, Anupriya Aggarwal, Jason K. K. Low, Rezwan Siddiquee, Caroline L. Ashley et al. · 2021 · ACS Central Science
  51. B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination
    Prerna Arora, Anzhalika Sidarovich, Nadine Krüger, Amy Madeleine Kempf, Inga Nehlmeier, Luise Graichen, Anna-Sophie Moldenhauer, Martin Sebastian Winkler, Sebastian R. Schulz, Hans‐Martin Jäck et al. · 2021 · Cell Reports
  52. Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein
    Suryadevara, Naveenchandra, Shrihari, Swathi, Gilchuk, Pavlo, VanBlargan, Laura A., Binshtein, Elad, Zost, Seth J., Nargi, Rachel S., Sutton, Rachel E., Winkler, Emma S., Chen, Elaine C. et al. · 2021
  53. Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies
    Renhong Yan, Ruoke Wang, Bin Ju, Jinfang Yu, Yuanyuan Zhang, Nan Liu, Jia Wang, Qi Zhang, Peng Chen, Bing Zhou et al. · 2021 · Cell Research
  54. A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody
    Nicholas C. Wu, Meng Yuan, Sandhya Bangaru, Deli Huang, Xueyong Zhu, Chang-Chun David Lee, Hannah L. Turner, Linghang Peng, Linlin Yang, Dennis R. Burton et al. · 2020 · PLoS Pathogens
  55. Cold sensitivity of the SARS-CoV-2 spike ectodomain
    Robert J. Edwards, Katayoun Mansouri, Victoria Stalls, Kartik Manne, Brian E. Watts, Robert Parks, Katarzyna Janowska, S. Gobeil, Megan Kopp, Dapeng Li et al. · 2021 · Nature Structural & Molecular Biology
  56. Longitudinal analysis of T cell receptor repertoires reveals shared patterns of antigen-specific response to SARS-CoV-2 infection
    Rachel M. Gittelman, Enrico Lavezzo, Thomas M. Snyder, Harus Jabran Zahid, Cara L. Carty, Rebecca Elyanow, Sudeb C. Dalai, Ilan Richard Kirsch, Lance Baldo, Laura Manuto et al. · 2022 · JCI Insight
  57. A haemagglutination test for rapid detection of antibodies to SARS-CoV-2
    Alain Townsend, Pramila Rijal, Julie Huiyuan Xiao, Tiong Kit Tan, Kuan-Ying Arthur Huang, Lisa M. Schimanski, Jiandong Huo, Nimesh Gupta, Rolle Rahikainen, Philippa Clare Matthews et al. · 2021 · Nature Communications
  58. Comparative Perturbation-Based Modeling of the SARS-CoV-2 Spike Protein Binding with Host Receptor and Neutralizing Antibodies: Structurally Adaptable Allosteric Communication Hotspots Define Spike Sites Targeted by Global Circulating Mutations
    Gennady M. Verkhivker, Steve Agajanian, Deniz Yaşar Öztaş, Grace Gupta · 2021 · Biochemistry
  59. SARS-CoV-2 spike S2-specific neutralizing antibodies
    Chia‐Jung Li, Shih‐Chung Chang · 2023 · Emerging Microbes & Infections
  60. Revealing the Threat of Emerging SARS-CoV-2 Mutations to Antibody Therapies
    Jiahui Chen, Kaifu Gao, Rui Wang, Guo‐Wei Wei · 2021 · Journal of Molecular Biology
  61. Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain
    Gabriele Cerutti, Yicheng Guo, Pengfei Wang, Manoj S. Nair, Maple Wang, Yaoxing Huang, Jian Yu, Lihong Liu, Phinikoula S. Katsamba, Fabiana A. Bahna et al. · 2021 · Cell Reports
  62. Potent human broadly SARS-CoV-2–neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2
    Cyril Planchais, Ignacio Fernández, Timothée Bruel, Guilherme Dias de Melo, Matthieu Prot, Maxime Beretta, Pablo Guardado‐Calvo, Jérémy Dufloo, Luis Manuel Molinos-Albert, Marija Backović et al. · 2022 · The Journal of Experimental Medicine
  63. A rapid cell-free expression and screening platform for antibody discovery
    Andrew C. Hunt, Bastian Vögeli, Ahmed O. Hassan, Laura Guerrero, Weston Kightlinger, Danielle J. Yoesep, Antje Krüger, Madison A. DeWinter, Michael Diamond, Ashty S. Karim et al. · 2023 · Nature Communications
  64. Seasonal coronavirus–specific B cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19
    Muriel Aguilar-Bretones, Brenda M. Westerhuis, Matthijs P. Raadsen, Erwin de Bruin, Felicity D. Chandler, Nisreen M.A. Okba, Bart L. Haagmans, Thomas Langerak, Henrik Endeman, Johannes P. C. van den Akker et al. · 2021 · Journal of Clinical Investigation
  65. SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 patients
    Roberto Gozalbo‐Rovira, Estela Giménez, Víctor Latorre, Clara Francés‐Gómez, Eliseo Albert, Javier Buesa, Alberto Marina, María Luisa Blasco, Jaime Signes‐Costa, Jesús Rodríguez‐Díaz et al. · 2020 · Journal of Clinical Virology
  66. Elucidation of interactions regulating conformational stability and dynamics of SARS-CoV-2 S-protein
    Takaharu Mori, Jaewoon Jung, Chigusa Kobayashi, Hisham Dokainish, Suyong Re, Yuji Sugita · 2021 · Biophysical Journal
  67. The inherent flexibility of receptor binding domains in SARS-CoV-2 spike protein
    Hisham M. Dokainish, Suyong Re, Takaharu Mori, Chigusa Kobayashi, Jaewoon Jung, Yuji Sugita · 2022 · eLife
  68. On-site airborne pathogen detection for infection risk mitigation
    Guangyu Qiu, Xiaole Zhang, Andrew J. deMello, Maosheng Yao, Junji Cao, Jing Wang · 2023 · Chemical Society Reviews
  69. SARS-CoV-2 Serum Neutralization Assay: A Traditional Tool for a Brand-New Virus
    Giulia Matusali, Francesca Colavita, Daniele Lapa, Silvia Meschi, Licia Bordi, Pierluca Piselli, Roberta Gagliardini, Angela Corpolongo, Emanuele Nicastri, Andrea Antinori et al. · 2021 · Viruses
  70. Development of a SARS-CoV-2 Vaccine Candidate Using Plant-Based Manufacturing and a Tobacco Mosaic Virus-like Nano-Particle
    Joshua M. Royal, Carrie A. Simpson, Alison A. McCormick, Amanda Phillips, Steve Hume, Josh Morton, John Shepherd, Youngjun Oh, Kelsi Swope, Jennifer DeBeauchamp et al. · 2021 · Vaccines
  71. Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants
    Chunyan Yi, Xiaoyu Sun, Yixiao Lin, Chenjian Gu, Longfei Ding, Xiaoxia Lü, Zhuo Yang, Yaguang Zhang, Liyan Ma, Wangpeng Gu et al. · 2021 · Genome Medicine
  72. Memory B cell responses to Omicron subvariants after SARS-CoV-2 mRNA breakthrough infection in humans
    Zijun Wang, Pengcheng Zhou, Frauke Muecksch, Alice Cho, Tarek Ben Tanfous, Marie Canis, Leander Witte, Brianna A. Johnson, Raphael Raspe, Fabian Schmidt et al. · 2022 · The Journal of Experimental Medicine
  73. Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies
    Maxwell T. Finkelstein, Adam G. Mermelstein, Emma Parker Miller, Paul C. Seth, Erik-Stephane D. Stancofski, Daniela Fera · 2021 · Viruses
  74. Landscape and selection of vaccine epitopes in SARS-CoV-2
    Christof C. Smith, Kelly Shea Olsen, Kaylee M. Gentry, Maria J. Sambade, Wolfgang A. Beck, Jason A. Garness, Sarah Entwistle, Caryn Willis, Steven P. Vensko II, Allison Woods et al. · 2021 · Genome Medicine
  75. Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class
    Micah Rapp, Yicheng Guo, Eswar R. Reddem, Jian Yu, Lihong Liu, Pengfei Wang, Gabriele Cerutti, Phinikoula S. Katsamba, Jude Saber Bimela, Fabiana A. Bahna et al. · 2021 · Cell Reports
  76. A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection
    Hejun Liu, M. Yuan, De-Li Huang, S. Bangaru, Fang-Zhu Zhao, C. D. Lee, Linghang Peng, Shawn Barman, Xue-Yong Zhu, D. Nemazee et al. · 2021 · Cell Host and Microbe
  77. Integrated Biophysical Modeling of the SARS-CoV-2 Spike Protein Binding and Allosteric Interactions with Antibodies
    Gennady M. Verkhivker, Luisa Di Paola · 2021 · The Journal of Physical Chemistry B
  78. Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain
    Adam K. Wheatley, Phillip Pymm, Robyn Esterbauer, Melanie H. Dietrich, Wen Shi Lee, Damien R. Drew, Hannah G. Kelly, Li‐Jin Chan, Francesca L. Mordant, Katrina A. Black et al. · 2021 · Cell Reports
  79. The landscape of antibody binding affinity in SARS-CoV-2 Omicron BA.1 evolution
    Alief Moulana, Thomas Dupic, Angela M. Phillips, Jeffrey Chang, Anne A. Roffler, Allison J. Greaney, Tyler N. Starr, Jesse D. Bloom, Michael M. Desai · 2023 · eLife
  80. A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding Domain
    Ling Niu, Kathryn N. Wittrock, Gage C. Clabaugh, Vikram Srivastava, Michael W. Cho · 2021 · Frontiers in Immunology
  81. Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses
    Wanting He, Rami Ghassan Musharrafieh, Ge Song, Katharina Dueker, Longping V. Tse, David R. Martinez, Alexandra Schäfer, Sean Callaghan, Peter Yong, Nathan Beutler et al. · 2022 · Nature Immunology
  82. SARS-CoV-2 structural features may explain limited neutralizing-antibody responses
    Martin F. Bachmann, Mona Omar Mohsen, Lisha Zha, Monique Vogel, Daniel E. Speiser · 2021 · npj Vaccines
  83. A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro
    Mary Hongying Cheng, Rebecca A. Porritt, Magali Noval Rivas, James Krieger, Asli Beyza Ozdemir, Gustavo Garcia, Vaithilingaraja Arumugaswami, Bettina C. Fries, Moshe Arditi, İvet Bahar · 2021 · Structure
  84. Paired Heavy and Light Chain Signatures Contribute to Potent SARS-CoV-2 Neutralization in Public Antibody Responses
    Bailey B. Banach, Gabriele Cerutti, Ahmed S. Fahad, Chen‐Hsiang Shen, Matheus Oliveira de Souza, Phinikoula S. Katsamba, Yaroslav Tsybovsky, Pengfei Wang, Manoj S. Nair, Yaoxing Huang et al. · 2020 · Cell Reports
  85. N-terminal domain mutations of the spike protein are structurally implicated in epitope recognition in emerging SARS-CoV-2 strains
    Apostolos Klinakis, Zoe Cournia, Theodoros N Rampias · 2021 · Computational and Structural Biotechnology Journal
  86. Molecular Aspects Concerning the Use of the SARS-CoV‑2 Receptor Binding Domain as a Target for Preventive Vaccines
    Yury Valdés-Balbín, Darielys Santana-Mederos, Françoise Paquet, Sonsire Fernández-Castillo, Yanet Climent, Fabrizio Chiodo, Laura Rodríguez, Belinda Sánchez Ramírez, Kalet León, Tays Hernández et al. · 2021 · ACS Central Science
  87. Development and application of therapeutic antibodies against COVID-19
    Lin-jin Ning, H. B. Abagna, Qianhu Jiang, Siqi Liu, Jian Huang · 2021 · International Journal on Biological Sciences
  88. Modeling how antibody responses may determine the efficacy of COVID-19 vaccines
    Pranesh Padmanabhan, Rajat Desikan, Narendra M. Dixit · 2022 · Nature Computational Science
  89. Neutralizing monoclonal antibodies elicited by mosaic RBD nanoparticles bind conserved sarbecovirus epitopes
    Chengcheng Fan, Alexander A. Cohen, Miso Park, Alfur Fu-Hsin Hung, Jennifer R. Keeffe, Priyanthi N.P. Gnanapragasam, Yu Erica Lee, Han Gao, Leesa M. Kakutani, Ziyan Wu et al. · 2022 · Immunity
  90. Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses
    Jared E. Feldman, Julia Bals, Clara G. Altomare, Kerri St. Denis, Evan Christopher Lam, Blake Marie Hauser, Larance Ronsard, Maya Sangesland, Thalia Bracamonte Moreno, Vintus Okonkwo et al. · 2021 · Science Immunology
  91. Impact of South African 501.V2 Variant on SARS-CoV-2 Spike Infectivity and Neutralization: A Structure-based Computational Assessment
    Mary Hongying Cheng, James Krieger, Burak Kaynak, Moshe Arditi, İvet Bahar · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  92. Kinetics of antibody responses dictate COVID-19 outcome
    Carolina Gonçalves de Oliveira Lucas, Jon Klein, Maria E. Sundaram, Feimei Liu, Patrick Wong, Júlio Dos Santos Silva, Tianyang Mao, Ji Eun Oh, Maria Tokuyama, Peiwen Lu et al. · 2020 · medRxiv
  93. Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env
    Amelia Escolano, Harry B. Gristick, Rajeev Gautam, Andrew T. DeLaitsch, Morgan E. Abernathy, Zhi Yang, Haoqing Wang, Magnus A. G. Hoffmann, Yoshiaki Nishimura, Zijun Wang et al. · 2021 · Science Translational Medicine
  94. Nicotinic cholinergic system and COVID-19: In silico identification of interactions between α7 nicotinic acetylcholine receptor and the cryptic epitopes of SARS-Co-V and SARS-CoV-2 Spike glycoproteins
    George Lagoumintzis, Christos T. Chasapis, N. Alexandris, D. Kouretas, S. Tzartos, E. Eliopoulos, K. Farsalinos, K. Poulas · 2021 · Food and Chemical Toxicology
  95. Emergence and outcomes of the SARS-CoV-2 ‘Marseille-4’ variant
    Pierre‐Edouard Fournier, Philippe Colson, Anthony Levasseur, Christian Albert Devaux, Philippe Gautret, Marielle Bedotto, Jérémy Delerce, Ludivine Bréchard, Lucile Pinault, Jean‐Christophe Lagier et al. · 2021 · International Journal of Infectious Diseases
  96. Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11
    J. Fedry, Daniel L. Hurdiss, Chunyan Wang, Wen-Tao Li, G. Obal, I. Drulyte, Wenjuan Du, S. Howes, F. V. van Kuppeveld, Friedrich G. Förster et al. · 2021 · Science Advances
  97. A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants
    Denise Haslwanter, M. Eugenia Dieterle, Anna Z. Wec, Cecilia M. O’Brien, Mrunal Sakharkar, Catalina Florez, Karen Tong, C. Garrett Rappazzo, Gorka Lasso, Olivia Vergnolle et al. · 2021 · mBio
  98. Antibody-dependent enhancement (ADE) of SARS-CoV-2 pseudoviral infection requires FcγRIIB and virus-antibody complex with bivalent interaction
    Shuang Wang, Junchao Wang, Xiaojuan Yu, Wen Jiang, Shuo Chen, Rongjuan Wang, Mingzhu Wang, Shasha Jiao, Wenbo Wang, Wenbo Wang et al. · 2022 · Communications Biology
  99. Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape
    Fuxing Lou, Maochen Li, Zehan Pang, Lin Jiang, Lin Guan, Lili Tian, Jiaming Hu, Junfen Fan, Huahao Fan · 2021 · Frontiers in Immunology
  100. Cross-reactive antibodies against human coronaviruses and the animal coronavirome suggest diagnostics for future zoonotic spillovers
    S. Klompus, S. Leviatan, T. Vogl, R. Mazor, I. Kalka, Liat Stoler-Barak, Nachum Nathan, Ayelet Peres, L. Moss, A. Godneva et al. · 2021 · Science immunology